Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Oct;3(5):883–889. doi: 10.1111/j.1365-2125.1976.tb00642.x

Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

G M Pacifici, M Nardini, P Ferrari, R Latini, C Fieschi, P L Morselli
PMCID: PMC1428941  PMID: 788761

Abstract

Amantadine, administered at a dose of 200 mg/day, antagonized the extapyramidal symptomatology induced by neuroleptic drugs in fifteen psychiatric patients. Steady-state levels were reached within 4-7 days of treatment. Individual plasma levels ranged from 200-900 ng/ml. Apparent plasma half-lives varied from 10-28.5 h with an apparent VD of 200-400 litres. A significant relationship was found between the plasma levels of amantadine and the effects on the extrapyramidal symptomatology. The data suggest a direct effect of amantadine on dopaminergic receptors.

Full text

PDF
883

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer R. B., McHenry J. T. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology. 1974 Aug;24(8):715–720. doi: 10.1212/wnl.24.8.715. [DOI] [PubMed] [Google Scholar]
  2. Biandrate P., Tognoni G., Belvedere G., Frigerio A., Rizzo M., Morselli P. L. A gas chromatographic method for the determination of amantadine in human plasma. J Chromatogr. 1972 Dec 6;74(1):31–34. doi: 10.1016/s0021-9673(01)94969-6. [DOI] [PubMed] [Google Scholar]
  3. Brown F., Redfern P. H. Proceedings: The effect of amantadine on the turnover of catecholamines in the rat brain. J Pharm Pharmacol. 1974 Dec;26 (Suppl):81P–82P. doi: 10.1111/j.2042-7158.1974.tb10106.x. [DOI] [PubMed] [Google Scholar]
  4. Fanali A., Nardini M., Sorgona F. Azione della amantadina nelle sindromi extrapiramidali da neurolettici. Sist Nerv. 1970 Sep-Oct;22(5):273–285. [PubMed] [Google Scholar]
  5. Farnebo L. O., Fuxe K., Goldstein M., Hamberger B., Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol. 1971 Sep;16(1):27–38. doi: 10.1016/0014-2999(71)90053-7. [DOI] [PubMed] [Google Scholar]
  6. Fieschi C., Nardini M., Casacchia M., Reitano M., Tedone M. E., Ferrari P., Robotti E. Terapia farmacologica della malattia di Parkinson con amantadina e levodopa. Sist Nerv. 1970 Mar-Jun;22(2):126–143. [PubMed] [Google Scholar]
  7. Fieschi C., Nardini M., Casacchia M., Tedone M. E. Amantadine for Parkinson's disease. Lancet. 1970 May 2;1(7653):945–946. doi: 10.1016/s0140-6736(70)91065-2. [DOI] [PubMed] [Google Scholar]
  8. Fieschi C., Nardini M., Casacchia M., Tedone M. E., Reitano M., Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. doi: 10.1016/s0140-6736(70)92742-x. [DOI] [PubMed] [Google Scholar]
  9. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
  10. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Sep 12;2(7672):566–566. doi: 10.1016/s0140-6736(70)91365-6. [DOI] [PubMed] [Google Scholar]
  11. Kelly J. T., Abuzzahab F. S., Sr The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):211–214. [PubMed] [Google Scholar]
  12. Maj J., Sowińska H., Baran L. The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia. 1972;24(2):296–307. doi: 10.1007/BF00403648. [DOI] [PubMed] [Google Scholar]
  13. Mann D. C., Pearce L. A., Waterbury L. D. Amantadine for Parkinson's disease. Neurology. 1971 Sep;21(9):958–962. doi: 10.1212/wnl.21.9.958. [DOI] [PubMed] [Google Scholar]
  14. Mawdsley C., Williams I. R., Pullar I. A., Davidson D. L., Kinloch N. E. Treatment of parkinsonism by amantadine and levodopa. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):575–583. doi: 10.1002/cpt1972134575. [DOI] [PubMed] [Google Scholar]
  15. Merrick E. M., Schmitt P. P. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Curr Ther Res Clin Exp. 1973 Aug;15(8):552–558. [PubMed] [Google Scholar]
  16. Nardini M., Fanali A., Sorgonà F., Vergnano M., Fieschi G. Studio clinico dell'amantadina nella sindrome extrapiramidale da neurolettici. Minerva Med. 1971 Oct 31;62(82):4020–4023. [PubMed] [Google Scholar]
  17. Papeschi R. Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology. 1974 Jan;13(1):77–83. doi: 10.1016/0028-3908(74)90009-4. [DOI] [PubMed] [Google Scholar]
  18. Scatton B., Cheramy A., Besson M. J., Glowinski J. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol. 1970;13(1):131–133. doi: 10.1016/0014-2999(70)90194-9. [DOI] [PubMed] [Google Scholar]
  19. Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]
  20. Schwab R. S., Poskanzer D. C., England A. C., Jr, Young R. R. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA. 1972 Nov 13;222(7):792–795. doi: 10.1001/jama.222.7.792. [DOI] [PubMed] [Google Scholar]
  21. Stone T. W., Bailey E. V. Responses of central neurones to amantadine: comparison with dopamine and amphetamine. Brain Res. 1975 Feb 21;85(1):126–129. doi: 10.1016/0006-8993(75)91017-3. [DOI] [PubMed] [Google Scholar]
  22. Stromberg U., Svensson T. H., Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. doi: 10.1111/j.2042-7158.1970.tb08487.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES